India grants country's first ever compulsory licence - for Bayer's Nexavar
This article was originally published in SRA
India has granted its first-ever compulsory licence in medicines with the issuing of an order that gives the Indian generics and biosimilar producer NATCO Pharma the right to produce and market a version of Bayer's anticancer, Nexavar (sorafenib tosylate), in the country1,2.
You may also be interested in...
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.